231 results on '"de Graeff, Pieter A."'
Search Results
2. Stand van zaken kleinschalige, passieve visserij in windparken op zee : Een bundeling van bestaande kennis en een verkenning naar de mogelijkheden voor kleinschalige, passieve visserij in windparken
3. Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder
4. Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study
5. Patient beliefs about medicines and quality of life after a clinical medication review and follow-up by a pharmaceutical care plan: a study in elderly polypharmacy patients with a cardiovascular disorder
6. Understanding drug preferences, different perspectives
7. The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands
8. Healthcare Professionals’ Self-Reported Experiences and Preferences Related to Direct Healthcare Professional Communications: A Survey Conducted in the Netherlands
9. Impact of Safety-Related Regulatory Action on Clinical Practice: A Systematic Review
10. Effect of Safety Issues with HIV Drugs on the Approval Process of Other Drugs in the Same Class: An Analysis of European Public Assessment Reports
11. Predictive Value Of Ambulatory Blood Pressure Shortly After Withdrawal Of Antihypertensive Drugs In Primary Care Patients
12. A Decade of Safety-Related Regulatory Action in the Netherlands: A Retrospective Analysis of Direct Healthcare Professional Communications from 1999 to 2009
13. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
14. Effect of First Myocardial Ischemic Event on Renal Function
15. Patiënten in geneesmiddelenonderzoek verschillen van latere gebruikers
16. The Additional Value of an e-Mail to Inform Healthcare Professionals of a Drug Safety Issue: 501.
17. The Role of the thorough QT Study in Drug Development: 431.
18. Dronedarone in High-Risk Permanent Atrial Fibrillation
19. Additional safety risk to exceptionally approved drugs in Europe?
20. Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter†
21. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy
22. Alterations in the Prognosis of Chronic Heart Failure: An Overview of the Major Mortality Trials
23. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats
24. A Drugʼs Life Cycle and Communication of Safety Issues: 468.
25. The 4S Study: Implications for Prescribing
26. Oral Contraceptives and the Absolute Risk of Venous Thromboembolism in Women With Single or Multiple Thrombophilic Defects: Results From a Retrospective Family Cohort Study
27. Does the Potential for Development of Streptokinase Antibodies Change the Risk-Benefit Ratio in Older Patients?
28. An educational programme for peer review groups to improve treatment of chronic heart failure and diabetes mellitus type 2 in general practice
29. Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure
30. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death
31. Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome : Executive summary
32. Myocardial Infarction Enhances Progressive Renal Damage in an Experimental Model for Cardio-Renal Interaction
33. Clinical Trial in Nephrology at Hard End Point?
34. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig
35. New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017
36. Perceived barriers for treatment of chronic heart failure in general practice; are they affecting performance?
37. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy
38. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases
39. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
40. The European Medicines Agency's approval of new medicines for type 2 diabetes
41. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
42. Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.
43. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment
44. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases
45. Risicocommunicatie over ernstige bijwerkingen: focus op Direct Healthcare Professional Communications
46. Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
47. The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors
48. Abstracts of papers clinical pharmacological meeting
49. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.
50. Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.